Literature DB >> 30005768

Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System: Review of the Supporting Evidence.

Anna Weiss1, Tari A King2, Kelly K Hunt3, Elizabeth A Mittendorf4.   

Abstract

The American Joint Committee on Cancer staging system has evolved in response to improved imaging, refined surgical techniques, enhanced pathologic evaluation, and greater understanding of tumor biology. The 8th edition has introduced clinical and pathologic prognostic stages for breast cancer that incorporate biologic variables (grade, estrogen/progesterone receptor status, HER2 status, multigene panels) with TNM categories that define the anatomic stage. The prognostic staging system facilitates more refined stratification than the anatomic stage with respect to survival and is an important advance that maintains the clinical relevance of the staging system by taking into account tumor biology and current treatment algorithms.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AJCC staging System; Anatomic stage; Biomarkers; Breast cancer; Prognostic stage

Mesh:

Substances:

Year:  2018        PMID: 30005768     DOI: 10.1016/j.suc.2018.03.005

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  11 in total

1.  Time to initiation of neo-adjuvant chemotherapy for breast cancer treatment does not influence patient survival: A study of US breast cancer patients.

Authors:  Devon Livingston-Rosanoff; Bret Hanlon; Nicholas Marka; Kara Vande Walle; Trista Stankowski-Drengler; Jessica Schumacher; Caprice C Greenberg; Heather Neuman; Lee G Wilke
Journal:  Breast J       Date:  2019-09-12       Impact factor: 2.431

2.  Refining breast cancer prognosis by incorporating age at diagnosis into clinical prognostic staging: introduction of a novel online calculator.

Authors:  Helen M Johnson; William Irish; Nasreen A Vohra; Jan H Wong
Journal:  Breast Cancer Res Treat       Date:  2021-02-20       Impact factor: 4.872

3.  Does Tumor Size Predict Response to Neoadjuvant Chemotherapy in the Modern Era of Biologically Driven Treatment? A Nationwide Study of US Breast Cancer Patients.

Authors:  Devon Livingston-Rosanoff; Jessica Schumacher; Kara Vande Walle; Trista Stankowski-Drengler; Caprice C Greenberg; Heather Neuman; Lee G Wilke
Journal:  Clin Breast Cancer       Date:  2019-06-06       Impact factor: 3.225

4.  Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx.

Authors:  Olga Kantor; Harold J Burstein; Tari A King; Steven Shak; Christy A Russell; Armando E Giuliano; Gabriel N Hortobagyi; Eric P Winer; Larissa A Korde; Joseph A Sparano; Elizabeth A Mittendorf
Journal:  Ann Surg Oncol       Date:  2022-07-27       Impact factor: 4.339

Review 5.  Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review.

Authors:  Mattia Garutti; Gaia Griguolo; Andrea Botticelli; Giulia Buzzatti; Carmine De Angelis; Lorenzo Gerratana; Chiara Molinelli; Vincenzo Adamo; Giampaolo Bianchini; Laura Biganzoli; Giuseppe Curigliano; Michelino De Laurentiis; Alessandra Fabi; Antonio Frassoldati; Alessandra Gennari; Caterina Marchiò; Francesco Perrone; Giuseppe Viale; Claudio Zamagni; Alberto Zambelli; Lucia Del Mastro; Sabino De Placido; Valentina Guarneri; Paolo Marchetti; Fabio Puglisi
Journal:  Cancers (Basel)       Date:  2022-04-09       Impact factor: 6.575

6.  Prognostic validation and treatment decision making of the 8th edition of the American Joint Committee on Cancer pathological staging system for elderly women with early-stage breast cancer.

Authors:  San-Gang Wu; Jian Shi; Wen-Wen Zhang; Jun Wang; Chen-Lu Lian; Jian Lei; Li Hua; Juan Zhou; Zhen-Yu He
Journal:  Aging (Albany NY)       Date:  2020-07-25       Impact factor: 5.682

7.  Validation of a Risk Score Incorporating Tumor Characteristics into the American Joint Committee on Cancer Anatomic Stage for Breast Cancer.

Authors:  Yi Heng Seow; Ru Xin Wong; John Heng Chi Lim; Weixiang Lian; Yoon Sim Yap; Fuh Yong Wong
Journal:  J Breast Cancer       Date:  2019-03-27       Impact factor: 3.588

8.  Distribution and Prognostic Significance of Estrogen Receptor α (ERα), Estrogen Receptor β (ERβ), and Human Epidermal Growth Factor Receptor 2 (HER-2) in Thyroid Carcinoma.

Authors:  Anjali Mishra; Niraj Kumari; Chandan Kumar Jha; Raouef Ahamed Bichoo; Shravan Kumar Mishra; Narendra Krishnani; Saroj Kanta Mishra
Journal:  J Thyroid Res       Date:  2020-05-05

9.  Staging for Breast Cancer With Internal Mammary Lymph Nodes Metastasis: Utility of Incorporating Biologic Factors.

Authors:  Chen-Lu Lian; Hai-Yan Zhang; Jun Wang; Jian Lei; Li Hua; Yong-Xiong Chen; San-Gang Wu
Journal:  Front Oncol       Date:  2021-01-14       Impact factor: 6.244

10.  Impact of Different Modules of 21-Gene Assay in Early Breast Cancer Patients.

Authors:  Mengdi Chen; Deyue Liu; Weilin Chen; Weiguo Chen; Kunwei Shen; Jiayi Wu; Li Zhu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-02       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.